Novel therapeutics in PD-1 refractory melanoma

This week’s podcast from VJOncology explores key advancements in the treatment of PD-1 refractory melanoma. Hear from leading experts, Alison Betoff Warner (Stanford University, Stanford, CA), Andrew Furness (Royal Marsden Hospital, London, UK), Anna Di Giacomo (University Hospital of Siena, Siena, Italy), María Vieito (Vall d’Hebron Institute of Oncology, Barcelona, Spain), and Yana Najjar (UPMC Hillman Cancer Center, Pittsburgh, PA), as they share insights into cutting-edge therapies and trials. Highlights include the FDA approval of TIL therapy in metastatic melanoma, early findings on off-the-shelf T-cell therapy, and results from the NIBIT-ML1 trial (NCT04250246) investigating a triple combination of ipilimumab, nivolumab, and ASTX727. Discover updates from the FIRELIGHT-1 study (NCT04985604) on tovorafenib and its efficacy across solid tumors, and learn about challenges in treating acryl and mucosal melanoma from the IGNYTE trial (NCT03767348) of RP1 and a Phase II trial (NCT04493203) of nivolumab with axitinib.